Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients

Kai Liu, Ying Chen, Ruzheng Lin, Kunyuan Han, Kai Liu, Ying Chen, Ruzheng Lin, Kunyuan Han

Abstract

Background: Due to the general susceptibility of new coronaviruses, the clinical characteristics and outcomes of elderly and young patients may be different.

Objective: To analyze the clinical characteristics of elderly patients with 2019 new-type coronavirus pneumonia (COVID-19).

Methods: This is a retrospective study of patients with new coronavirus pneumonia (COVID-19) who were hospitalized in Hainan Provincial People's Hospital from January 15, 2020 to February 18, 2020. Compare the clinical characteristics of elderly with Young and Middle-aged patients.

Results: A total of 56 patients were enrolled 18 elderly patients (32.14%), and 38 young and middle-aged patients (67.86%). The most common symptoms in both groups were fever, followed by cough and sputum. Four patients in the elderly group received negative pressure ICU for mechanical ventilation, and five patients in the young and middle-aged group. One patient died in the elderly group (5.56%), and two patients died in the young and middle-aged group (5.26%). The PSI score of the elderly group was higher than that of the young and middle-aged group (P < 0.001). The proportion of patients with PSI grades IV and V was significantly higher in the elderly group than in the young and middle-aged group (P < 0.05). The proportion of multiple lobe involvement in the elderly group was higher than that in the young and middle-aged group (P < 0.001), and there was no difference in single lobe lesions between the two groups. The proportion of lymphocytes in the elderly group was significantly lower than that in the young and middle-aged group (P < 0.001), and the C-reactive protein was significantly higher in the young group (P < 0.001). The Lopinavir and Ritonavir Tablets, Chinese medicine, oxygen therapy, and mechanical ventilation were statistically different in the elderly group and the young and middle-aged group, and the P values were all <0.05.

Interpretation: The mortality of elderly patients with COVID-19 is higher than that of young and middle-aged patients, and the proportion of patients with PSI grade IV and V is significantly higher than that of young and middle-aged patients. Elderly patients with COVID-19 are more likely to progress to severe disease.

Keywords: COVID-19; Clinical feature; Elderly patients; Young and middle-aged patients.

Conflict of interest statement

Declaration of Competing Interest None declared.

Copyright © 2020. Published by Elsevier Ltd.

References

    1. Li J.-.Y., You Z. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020 In press, journal pre-proof Available online 20 February 2020.
    1. Guan W.J., Ni Z.Y., Zhong N.S., et al. Clinical characteristics of 2019 novel coronavirus infection in China. Med Rxiv, 2020, [Epub ahead of print]. 10.1101/2020.02.06.20020974.
    1. Yang Y., Lu Q.B., Liu M.J., et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. Med Rxiv, 2020, [Epub ahead of print]. DOI: 10.1101/2020.02.10.20021675
    1. Liu Y., Gayle A.A., Wilder-Smith A. The reproductive number of COVID−19 is higher compared to SARS coronavirus. J Travel Med. 2020 doi: 10.1093/jtm/taaa021. [Epub ahead of print]
    1. Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERSepidemic. Asian Pac J Allergy Immunol. 2020 doi: 10.12932/AP-200220-0772.
    1. Park M., Thwaites R.S., Openshaw P.J.M. COVID-19: lessons from SARS and MERS. Eur J Immunol. 2020 doi: 10.1002/eji.202070035.
    1. Yao T.T., Qian J.D., Zhu W.Y. A systematic review of lopinavir therapy for sars coronavirus and mers coronavirus-a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020 doi: 10.1002/jmv.25729.
    1. Zuo M.Z., Huang Y.G., Ma W.H. Expert recommendations for tracheal intubation in critically ill patients with noval coronavirusdisease 2019. Chin Med Sci J. 2020 doi: 10.24920/003724.
    1. Xu J., Zhao S., Teng T. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020 Feb 22;12(2) doi: 10.3390/v12020244. pii: E244.
    1. Peeri N.C., Shrestha N., Rahman M.S. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020 doi: 10.1093/ije/dyaa033. pii: dyaa033.
    1. Lin C., Ding Y., Xie B. Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease. Clin Imaging. 2020;63:7–9. doi: 10.1016/j.clinimag.2020.02.008.
    1. Xu X.W., Wu X.X., Jiang X.G. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606. doi: 10.1136/bmj.m606.
    1. Liu W., Tao Z.W., Lei W. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novelcoronavirus disease. Chin Med J. 2020 doi: 10.1097/CM9.0000000000000775.
    1. Wang N.L., Jie Y., Tao F.B. Precautions in ophthalmic practice in the prevention and control of the novel coronaviruspneumonia epidemic. Zhonghua Yan Ke Za Zhi. 2020;56(0):E007. doi: 10.3760/cma.j.cn112142-20200224-00102.
    1. Tian S., Hu W., Niu L. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020 doi: 10.1016/j.jtho.2020.02.010. pii: S1556-0864(20)30132-5.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere